Table 1. Summary of information for all enrollments.
| Clinical characteristics | ESCC | Non-ESCC | P value |
|---|---|---|---|
| Age | |||
| Mean ± SD | 57.7±7.5 | 57.0±8.6 | >0.05 |
| Gender | >0.05 | ||
| Male | 22 (73%) | 18 (60%) | |
| Female | 8 (27%) | 12 (40%) | |
| Pathological grade | <0.05 | ||
| Stage I | 6 (20%) | 9 (30%) | |
| Stage II | 4 (13%) | 12 (40%) | |
| Stage III | 17 (57%) | 8 (27%) | |
| Stage IV | 3 (10%) | 1 (3%) | |
| Tumor location | |||
| Upper 1/3 | 3 (10%) | NA | |
| Middle 1/3 | 16 (53%) | NA | |
| Lower 1/3 | 11 (37%) | NA | |
| Differentiation grade | NA | ||
| Well | 5 (17%) | NA | |
| Moderately | 15 (50%) | NA | |
| Poor | 10 (33%) | NA | |
| Serum tumor marker elevation | |||
| CA199 | 0 in 18 | 1 in 21 | |
| CEA | 2 in 25 | 7 in 25 | |
| CA125 | 0 in 20 | 2 in 22 | |
| AFP | 0 in 14 | 3 in 22 | |
ESCC, esophageal squamous carcinoma; CA199, cancer antigen 19-9; CEA, carcinoembryonic antigen; CA125, cancer antigen 125; AFP, alpha fetoprotein.